PDA Training Container Closure Systems

Development of Container Closure Systems
• Set-up of target profile
• Packaging materials
• Modification of materials
• Extractables & Leachables (E&L) testing
• Permeability
• Light transmission
• Processability
• Functional testing
• Container closure integrity (CCI)
• Shipping assessment
• Combination products
Formulation
- Solid, semi-solid, liquid
- Lyophilisate for reconstitution
- Patient related dosing (e.g. body weight or surface)
- Concentration of active ingredient
- Pharmacological activity of active ingredient
- Content of volatile components (e.g. alcohols)
- Preservatives and/or other critical excipients
Route of administration and application

- Oral, topical, *parenteral* (sc, im, iv – injection/infusion), others
- Use of application aids for product preparation (infusion sets, spikes, disposable syringes)
- Application with injectors (mechanical, automated)
  - Injection speed
  - Needle size
  - Resistance against mechanical stress (e.g. pressure resistance)
User profile

- Application by professionals (nurses, physician) or by patients
  - Fool proof system vs. complex equipment
  - Known system vs. need for intense training
- Age and/or impairment of patients
  - Size of systems
  - Ease of use, easy to understand
  - Safety, hygiene
• Influence of humidity
  • Barrier films
  • Alu-pouch for plastic infusion bags
• Influence of light
  • Light resistant (colored) glass
  • Light protection via secondary container
• Influence of gases (O$_2$, NO$_x$, CO$_2$)
• Other environmental influences on product quality
  • Temperature controlled storage and shipment
  • -70°C storage
Marketing area
- USA, EU, Japan, others (consideration of climatic zones)
- Different pharmacopoeial requirements
- Cultural, political and social specifics
  - Japan: „We are a zero fault country”
Processability
- Aseptic processing
- Lyophilization
- Sterilization (e.g. for plastic packaging components)
- Processability on existing equipment
- Development of new process technology
Other Aspects
• Stability target (t and T)
• Child resistant packaging/ Senior friendly packaging
• Supply safety of basic materials, components or packaging solutions
• Anticounterfeiting
• ……
Materials used for containers for Parenterals are

- Glass: type I and II, colorless and amber
- Plastics: PE, PP, COC, COP, PVC
- Rubber: Bromobutyl-, Chlorobutyl-, Butylrubber, synthetic Polyisoprene
Plastic/Rubber challenges

- Leachables from plastics are mostly organic components of the material
  - Monomers, oligomers of basic polymer
  - Curing system (for rubber components)
  - Additives: UV-stabilizer, plasticizer, antioxidants
  - Inorganic filler or colorants
- Plastic components are less heat resistant compared to glass
  - Depyrogenization by heating up to 300°C impossible
- Container size, fill volume and storage conditions are influencing the amount of leachables
Glass challenges

- Leachables from glass are inorganic components of the glass bulk material
  - major extractables: Si and Na
  - minor extractables: K, B, Ca, Al
  - trace extractables: Fe (in colored glass)
- The composition of the filling impacts the extent of extraction, especially:
  - pH, type of buffer system, surfactants, complexing agents
- Container size, fill volume and storage conditions are influencing the amount of leachables
- Manufacturing processes (e.g. sterilization time and temperature) impact the extent of leaching
Glass challenges: Influence of storage time on Alkali-release

1 ml ampoules filled with WFI
Ampoules were autoclaved for 20 minutes at 121°C
Na₂O was measured by flame photometry

source: Dr. J. Pfeifer, Schott-Rohrglas GmbH, DPhG Fachgruppentagung Analytik 2003
Requirements for packaging solutions for Biologics

- Containers or container components needs to be able to be handled in aseptic processes
  - Sterilized/ depyrogenized in the process (e.g. glass heating to > 300°C)
  - Manufactured to be used in aseptic processes without manipulation (e.g. RTF quality of components)
- Low leaching potential of the container materials
- Low adhesion/ absorption potential of the container materials
- Mechanical stability for storage and shipment, e.g. below freezing point
Surface coatings on packaging component are used to reduce the amount of leachables by “sealing” the packaging material. Coatings are feasible for glass, rubber and plastics. Examples for coatings are:
- Silicone oil on glass and plastics
- SiOx on glass
- Teflon on rubber
Coating of glass surfaces

source: Schott - Product brochure type I plus
Coating of glass surfaces

Evaluation: autoclaving at 121°C for 6h, AAS-analysis:

<table>
<thead>
<tr>
<th></th>
<th>type I</th>
<th>type I plus®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na⁺</td>
<td>3.5 ppm</td>
<td>&lt; 0.01 ppm</td>
</tr>
<tr>
<td>Ca²⁺</td>
<td>1.1 ppm</td>
<td>&lt; 0.05 ppm</td>
</tr>
<tr>
<td>B³⁺</td>
<td>3.5 ppm</td>
<td>&lt; 0.1 ppm</td>
</tr>
<tr>
<td>Si⁴⁺</td>
<td>5.0 ppm</td>
<td>&lt; 0.3 ppm</td>
</tr>
<tr>
<td>Al³⁺</td>
<td>2.3 ppm</td>
<td>&lt; 0.05 ppm</td>
</tr>
</tbody>
</table>

source: Schott - Product brochure type I plus
Coating of rubber surfaces – The Eprex® case

- August 2003: Johnson & Johnson recalled certain batches of prefilled syringes of the anemia drug, Eprex, due to a significant increase of the incidence of a severe adverse event (pure red cell aplasia = PRCA)
- The root cause was a leachable from the rubber closure, which was found in the drug after a drug reformulation
- The issue could be solved by coating of the rubber surface with a teflon film. The leachable was no longer detectable in the drug, the incidence of PRCA decreased significantly
Extractables testing

Identification of potential leachables

- Toxicological assessment of extractables considering the use of the product (route of administration, frequency of use, patient population, etc.)
- Select analytical targets for establishment of quantitative and specific methods for leachables testing
- Specify the analytical threshold for relevant targets

Definition/ set-up of leachables study
Leachables testing

Leachables study
• Selection of analytical targets after extractables study and toxicological assessment
• Analytical methods
  • GC + detection with FID, ECD or MS
  • HPLC + detection with UV/DAD or MS
  • ICP-OES for inorganic leachables
• Development and validation of quantitative analytical methods
• Conduct leachables analysis as part of formal stability studies

_understand the quantities of leachables over product shelf-life to enable toxicological assessment of the drug product - leachables can be regarded as a special type of impurities_
Regulatory requirements (for semi-permeable containers)

- For semi-permeable containers ICH-guideline Q1A (Stability Testing of New Drug Substances and Products) requires specific storage conditions for stability testing.
- The conditions for accelerated testing are 40 ± 2°C at not more than (NMT) 25%RH.
- 6 months data from these conditions are required for submission.
Tight secondary container for high permeable packaging

**Method:**
gravimetric measurement + subsequent calculation
Tight secondary container for high permeable packaging

**The risk:**
Mold formation due to humid climate in tight pouches

Mold on label

Mold on Al-foil
Method description

glass fragment is prepared from container

fragment is scanned in a UV photometer between 290 and 550 nm

light transmission is calculated from the scan

Transmission limit of light protecting containers acc. to Ph.Eur. 3.2.1
Case study: Infusion bag X-ray contrast agent

Is there any light protection by the immediate or secondary container?
Case study: Infusion bag X-ray contrast agent

**Test description**

Place film in UV-photometer

Scan from 800 to 200 nm

⇒ light protection is integrated into secondary container
Sterilization conditions - Melting characteristics of polymers evaluated bei DSC

Diagram showing melting characteristics of COC, PP, and PE polymers with temperature (°C) on the x-axis and power (mW) on the y-axis.
Cleaning of parenteral containers (glass ampoules)
Plunger movement of prefilled syringes during autoclaving

**Conditions:**
- 150 ml PP-syringe
- 121°C/ 20 min
- 3.5 bar counter pressure

![Graph showing plunger movement](image)
Manufacturing process – Lubrication process

- Annealing of silicone oil
  - Spray-on of silicone-oil emulsion with low viscosity (350 – 1000 cSt)
  - Heat annealing, e.g. 10 min. at 300°C

- Direct application of silicone oil on barrel surface
  - Spray-on of silicone oil with high viscosity ($\geq$ 1000 cSt)

- For glass barrels both processes are possible, for plastic barrels only direct application is possible
Manufacturing process – Lubrication glass barrel

- Silicone oil amount (mg/barrel)
Manufacturing process – Lubrication glass barrels

- Silicone oil distribution
Use test – Case study

**Description:**
1st evacuation diluent (saline) without needle
2nd evacuation reconstituted lyophilisate with 27G-needle
Use test – Influence of attached canula

![Bar chart showing the influence of attached canula on running force (N) for different gauges (27G, 28G, 29G, 30G) across three charges (Charge 1, Charge 2, Charge 3). The chart illustrates the variation in running force with the different gauges and charges.]
Use test – Influence of flow rate

![Graph showing the influence of flow rate on syringe plunger movement and pressure inside the syringe.](image)
Use test – Influence of viscosity of filling

![Graph showing the influence of viscosity on plunger movement and pressure inside the syringe. The graph compares three different viscosities: 1.0 mPa*s (cP), 8.4 mPa*s (cP), and 20.9 mPa*s (cP).]
Definition - Container Closure Integrity (CCI)

- The ability of the container-closure system to maintain the integrity of its microbial barrier, and, hence, the sterility of a drug product throughout its shelf life.

- Container Closure Integrity (CCI) is proven, when a package meets the maximum allowable leakage limit required to ensure product quality attributes of sterility and physicochemical stability through expiry. (USP <1207>)
Why is leakage critical?

- Risks microbial ingress
  - sterility loss
- Loss of critical headspace gases/ intrusion of normal atmosphere
  - instability
- Loss of headspace vacuum
  - instability
  - product access difficulty
When to test CCI?

- Development of container closure system (CCS)
- Manufacturing process (e.g. sterilisation parameters)
- Preparation of packaging components (e.g. lubrication, cleaning, surface treatment)
- Variability of composition and dimensions of packaging components and/or materials as well as defects
- Variability of manufacturing processes (e.g. torque adjustment or sealing parameters)
The ideal CCI test

- Non-destructive
- Reliable (covering all potential defects)
- 100% inspection in-line
- Feasible for stability testing
Regulatory Background - USP

〈1207〉 Package Integrity Evaluation - Sterile Products
• 〈1207.1〉 Package Integrity Testing in the Product Life Cycle - Test Method Selection and Validation
• 〈1207.2〉 Package Integrity Leak Test Technologies
• 〈1207.3〉 Package Seal Quality Test Technologies
Regulatory Background - USP

1207 Package Integrity Evaluation - Sterile Products

- Definitions
  - Package Integrity = Container Closure Integrity (CCI): the absence of package leakage greater than the product package maximum allowable leakage limit (MALL)
  - Integral package
  - Leak Tests (CCIT)
  - Seal Quality Tests (SQT)
Regulatory Background - USP

1207.1 Package Integrity Testing in the Product Life Cycle - Test Method Selection and Validation

- Product life cycle testing
  - Product package development and validation
  - Routine manufacturing
  - Marketed product stability
Regulatory Background - USP

(1207.1) Package Integrity Testing in the Product Life Cycle - Test Method Selection and Validation

• Leak test selection criteria
  • Package content
  • Package design and materials of construction
  • Product package maximum allowable leakage limit
  • Deterministic vs. probabilistic methods
  • Method limit of detection (LOD)
  • Method largest leak detection capability
  • Method outcome
  • Quantitative vs. qualitative
  • Nondestructive vs. destructive
  • On-line vs. off-line
Regulatory Background - USP

(1207.2) Package Integrity Leak Test Technologies
• Technologies categorization review

<table>
<thead>
<tr>
<th>Deterministic methods</th>
<th>Probabilistic methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reproducible</td>
<td>Not reproducible</td>
</tr>
<tr>
<td>Sensitive</td>
<td>Insensitive</td>
</tr>
<tr>
<td>Highly instrumental</td>
<td>Little or no instrumentation used</td>
</tr>
<tr>
<td>Quantitative test result outcome</td>
<td>Qualitative, interpretive results</td>
</tr>
<tr>
<td>Minimal test sample preparation or manipulation</td>
<td>Considerable test sample preparation and/or manipulation</td>
</tr>
<tr>
<td><strong>Risk of error - LOW</strong></td>
<td><strong>Risk of error - HIGH</strong></td>
</tr>
</tbody>
</table>
Regulatory Background - USP

(1207.2) Package Integrity Leak Test Technologies

- Leak test technologies

<table>
<thead>
<tr>
<th>Deterministic methods</th>
<th>Probabilistic methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electrical conductivity and capacitance test (HVLD)</td>
<td>Microbial challenge by immersion</td>
</tr>
<tr>
<td>Laser based headspace analysis</td>
<td>Tracer liquid tests (e.g. dye)</td>
</tr>
<tr>
<td>Mass extraction</td>
<td>Bubble tests</td>
</tr>
<tr>
<td>Pressure decay</td>
<td>Tracer gas (sniffer mode)</td>
</tr>
<tr>
<td>Tracer gas (vacuum mode)</td>
<td></td>
</tr>
<tr>
<td>Vacuum decay</td>
<td></td>
</tr>
</tbody>
</table>

*The methods are examples and are not binding!*
Regulatory Background - USP

(1207.3) Package Seal Quality Test Technologies

• Seal quality test methods
  • properly characterize and monitor seal quality
  • ensure consistency of package assembly
  • methods (not binding!)
    – Airborne ultrasound                ASTM F3004
    – Cap application/ removal torque    ASTM D2063, D3198, etc.
    – Package burst test                 ASTM F1140, F2084
    – Package seal strength (peel) test  ASTM F88
    – Residual seal force

Container closure integrity (CCI)
Introduction

- Pharmaceutical products are more and more manufactured at one site and distributed globally, esp. complex products like biologicals or prefilled syringes
- Shipping of pharmaceutical products is done with standard equipment already established for global cargo shipment
- The relevant regulations are not pharma specific but specific with regard to shipping safety (e.g. IATA air shipment regulations)
- Critical aspects for pharma products are temperature, air pressure and mechanical stress
Shipping Conditions - Temperature conditions

- Freezing of liquid products may lead to breakage of the container
- Freezing/thawing of liquids may lead to changes of functionality, e.g. friction forces of prefilled syringes
- Freezing/thawing of liquids may impact integrity due to plunger movement in prefilled syringes
- Materials are not suitable for shipping conditions – e.g. -70°C shipping
- Pharmaceutical standard rubber materials have glass transition temperature around -55 to 60 °C and are thus brittle at shipping temperature
- To solve the issue innovative approaches are required – one commercially available component is a „hybrid“ injection stopper:
  - The rubber material in contact to the drug is a standard pharmaceutical rubber
  - The rubber material sealing the vial has a glass transition temperature below -80°C and is thus elastic under shipping conditions
Shipping Conditions - Pressure conditions

Pressurization during air shipment: Reduction of cabin pressure down to approx. 800 mbar – even in the cargo cabin.

Source: Post, E., Container Closure Integrity Test (CCIT), PDA Europe Conference, 07/2013
Case Study - Product shipment on dry ice (Lighthouse)

Source:
D. Duncan: Container Closure Integrity of Sterile Vials During Deep Cold Storage – Presentation on PDA Europe Parenteral Packaging Conference, Prague 2013
Case Study - Product shipment on dry ice (Lighthouse)

The issue:
• Air filled vial at 1 atm at room temperature
• On dry ice (-78 °C) the initial headspace condenses and creates underpressure
• The stopper can lose its elastic properties and closure can be lost
• Cold dense CO₂ from environment fills headspace
• Warming container to room temperature regains stopper elasticity and reseals closure
Case Study - Product shipment on dry ice (Lighthouse)

Test method/study set-up:
• Ten sets of vials/stopper combinations (different materials, different sealing conditions) were manufactured at 1 atm at room conditions
• The samples were stored on dry ice and analyzed after warming up to room conditions
• Quantifying of the physical headspace conditions was performed with Laser-based Headspace Analysis
Case Study - Product shipment on dry ice (Lighthouse)

Results: Vials with $O_2 < 17\%$

<table>
<thead>
<tr>
<th>Set</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>27</td>
</tr>
<tr>
<td>3</td>
<td>39</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>9</td>
<td>31</td>
</tr>
<tr>
<td>10</td>
<td>0</td>
</tr>
</tbody>
</table>
Temperature controlled shipment

- More and more products need to be shipped under controlled temperature conditions (e.g. Biologicals)
- Depending on the timely length of the shipment and the product specific temperature conditions, specific systems need to be developed.
- The system comprises a container, cooling elements as well as the exact temperature to which the elements need to be temperatured
- For temperature controlled shipment two principles are feasible
  - Active systems, which require power source (cable, battery)
  - Passive systems, based on cooling elements and a suitable packaging system
- For the evaluation of Cold Chain Supply solution the length of the shipment and the respective environmental conditions (winter, summer) need to be considered
- For validation of Cold Chain shipments test cycles were agreed by standardization groups (ISTA, DIN)
Phase change materials (PCM)
– Scientific background

Phase Change Materials (PCM) provide the best temperature buffer in the temperature range of their melting point. The graph compares a water and a paraffin filled PCM element regarding their cooling/heating properties.
Phase change materials (PCM) – Description

0 % PCM aktiv 100 % PCM aktiv
Complete packaging solution

Packaging scheme

Real box
Evaluation of a Cold Chain package (2 to 8 °C shipment)

Thermosensors are located at different positions of the entire box.

The box is stored at conditions simulating a shipment in the summer.

The curves show the temperature at different points of the box.
Definition

- Term “Combination Product” not defined in EU
- Drug-delivery product = Drug/Device
- Medical Device incorporating medicinal substance or an ancillary human blood derivative = Medical Device/Drug
- Pre-condition: fix combined (integral) and not only co-packed

- Medical Device/Drug: MDD 93/42/EEC or AIMDD 90/385/EEC
Definition

Examples

• Drug-delivery product (Drug/Device):
  • Pre-filled syringe

• Medical Device incorporating medicinal substance or an ancillary human blood derivative (Medical Device/Drug)
  • Drug-eluting stent
Definition


  **This rule is effective as of July 22nd, 2013**

- FDA Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products (January 2017)
Definition

• Drug/device
• Biologic/device
• Drug/biologic
• Drug/device/biologic

• Single entity (e.g. pre-filled syringe, drug-eluting stent)
• Co-packed product (e.g. surgical or first aid kit)
• Cross-labeled products (e.g. a light-emitting device and a light-activated drug)
Thank you very much for your attention!!